Dae-Sung Kim
Directeur/Bestuurslid bij Great Orient Chemical Pte Ltd.
Profiel
Dae-Sung Kim is currently a Director at Great Orient Chemical Pte Ltd.
and an Auditor at ID Biochem, Inc. He was previously the Chief Executive Officer & Director at ISU Abxis Co., Ltd.
from 2014 to 2017, Director, Executive Director & Director-Finance at ISU CHEMICAL CO., LTD.
from 2011 to 2012, and Director & Vice President at ISU Petasys Co., Ltd.
He obtained an undergraduate degree from Seoul National University.
Actieve functies van Dae-Sung Kim
Bedrijven | Functie | Begin |
---|---|---|
ID Biochem, Inc.
ID Biochem, Inc. Chemicals: SpecialtyProcess Industries Part of Pharmicell Co., Ltd., ID Biochem, Inc. is a South Korean company based in Ulsan, South Korea. The company specializes in the production of pharmaceuticals, including vaccines, anti-cancer drugs, and stem cell therapies. In 2012, ID Biochem was acquired by Pharmicell Co., Ltd. for $19.28 million. | Comptroller/Controller/Auditor | - |
Great Orient Chemical Pte Ltd. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Dae-Sung Kim
Bedrijven | Functie | Einde |
---|---|---|
ISU ABXIS CO., LTD. | Algemeen Directeur | 24-03-2017 |
ISU PETASYS CO., LTD. | Directeur/Bestuurslid | - |
ISU CHEMICAL CO., LTD | Financieel Directeur/CFO | - |
Opleiding van Dae-Sung Kim
Seoul National University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
ISU CHEMICAL CO., LTD | Process Industries |
ISU ABXIS CO., LTD. | Health Technology |
ISU PETASYS CO., LTD. | Electronic Technology |
Bedrijven in privébezit | 2 |
---|---|
ID Biochem, Inc.
ID Biochem, Inc. Chemicals: SpecialtyProcess Industries Part of Pharmicell Co., Ltd., ID Biochem, Inc. is a South Korean company based in Ulsan, South Korea. The company specializes in the production of pharmaceuticals, including vaccines, anti-cancer drugs, and stem cell therapies. In 2012, ID Biochem was acquired by Pharmicell Co., Ltd. for $19.28 million. | Process Industries |
Great Orient Chemical Pte Ltd. |